Paper Details

  1. Home
  2. Paper Details

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).

Author: AparicioThomas, ArtruPascal, AsnaciosAmani, BonnetainFranck, DubreuilOlivier, Dupont-GossardAnne-Claire, FeinFrancine, GauthierMélanie, LandiBruno, LecomteThierry, LobryCéline, MalkaDavid, Manet-LacombeSophie, TaïebJulien, Thirot-BidaultAnne, TrouilloudIsabelle, ZaananAziz

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This review explores the potential of a sequential treatment approach alternating irinotecan, fluorouracil, and gemcitabine for patients with metastatic pancreatic cancer. Standard of care regimens currently use irinotecan/fluorouracil-based and gemcitabine-based therapies.
Paper Details　
Original Abstract of the Article :
Fluorouracil and irinotecan-based, and gemcitabine-based regimens, are the standard of care in the first-line treatment of patients with metastatic pancreatic cancer. New approaches are needed to improve survival and quality of life. Whether a sequential approach alternating irinotecan, fluorouracil...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejca.2014.09.015

データ提供：米国国立医学図書館（NLM）

Fighting Pancreatic Cancer: A Camel's Perspective on New Treatment Strategies

Pancreatic cancer is a formidable foe, often difficult to treat effectively. This research explores the potential of a sequential approach to treating metastatic pancreatic cancer, alternating between gemcitabine-based and irinotecan, fluorouracil-based regimens. It's like finding a new route through a challenging desert terrain, searching for a more effective way to combat this disease.

A New Path to Combat Pancreatic Cancer: Finding a More Effective Approach

The research explores the effectiveness and tolerability of this sequential approach, seeking to improve survival rates and quality of life for patients with metastatic pancreatic cancer. It's like testing different types of sand dunes for their stability and navigability, searching for the best strategy to navigate the treacherous terrain of this disease.

A Desert Journey for Better Treatment: Hope for a Brighter Future

This research offers a glimpse of hope for patients with metastatic pancreatic cancer. It highlights the potential of exploring new and innovative treatment approaches to improve survival rates and quality of life. Just as a camel caravan relies on a guide to navigate the desert, researchers are continually seeking better ways to fight this challenging disease, offering hope for a brighter future for those affected.

Dr. Camel's Conclusion

This research explores the potential of a sequential treatment approach for metastatic pancreatic cancer, offering a new perspective on fighting this challenging disease. It's like discovering a new oasis in the vast desert of cancer research, providing hope for a more effective and compassionate approach to treatment. This research serves as a reminder that even in the face of formidable challenges, we must continue to explore new pathways and seek innovative solutions to improve the lives of those battling this disease.

Date :
  1. Date Completed 2015-01-27
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

25454414

DOI: Digital Object Identifier

10.1016/j.ejca.2014.09.015

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.